Clinical trials: Liraglutide
Osteoarthritis, Obesity
Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness
This is a substudy to a randomised trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864).
- Trial name
- NCT03208881
- Testing
- Dietary Supplement: Intensive dietary intervention
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- Henrik Gudbergsen
Type 2 Diabetes, Peripheral Vascular Disorder Due to Diabetes Mellitus
Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
Diabetic lower extremity arterial disease ( DLEAD ), is a common complication of type 2 diabetes. However, DLEAD remains less studied than other diabetic vascular complications; and only few randomised controlled trials (RCTs)…
- Trial name
- NCT04146155
- Testing
- Liraglutide+standard-of-care treatment, standard-of-care treatment
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gastroparesis, Functional Dyspepsia
Effects of Liraglutide on Body Surface Gastric Mapping
Aim 1: To investigate, in healthy participants, the effect of liraglutide injection on gastric electrophysiology (as measured by body surface gastric mapping using the Gastric Alimetry device) during an 13-dayramping dose of…
- Conditions
- Gastroparesis, Functional Dyspepsia, Chronic Nausea and Vomiting Syndrome, Healthy
- Trial name
- NCT06500130
- Testing
- Body Surface Gastric Mapping
- Where
- New Zealand
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Alimetry
Bile Acid Malabsorption
Treatment of Bile Acid Malabsorption With Liraglutide
Comparing the effect of Liraglutide on bile acid malabsorption, with colesevelam
- Trial name
- BAM-LIRA (NCT03955575)
- Testing
- Liraglutide 6 MG/ML, Colesevelam
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Filip Krag Knop
Type 1 Diabetes
Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes
This is the first prospective randomized double-blind placebo-controlled study to investigate the effect of a GLP-1 analog, specifically liraglutide, on blood glucose levels and variability in subjects with type 1 diabetes…
- Trial name
- NCT01722227
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University at Buffalo
Type II Diabetes in Subjects BMI 27 to 32
Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment
Investigators aim to show that Roux-en-Y Gastric Bypass (RYGB) is superior to best medical treatment in reaching well-defined treatment end points in Asian subjects of BMI 27-32 with type 2 Diabetes (DM2).
- Trial name
- NCT02041234
- Testing
- Roux-en-Y Gastric Bypass (RYGB), Incretin analogues, Xenical
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Khoo Teck Puat Hospital
Gestational Diabetes
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
Obese women with history of gestational diabetes are in great danger to develop type 2 diabetes (T2D) within 5-10 years after delivery.
- Trial name
- Liragest (NCT04324229)
- Testing
- Liraglutide 6 MG/ML [Victoza]
- Where
- Finland
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Turku University Hospital
Metabolism and Nutrition Disorder, Obesity
Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin
This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.
- Trial name
- SCALE™ Insulin (NCT02963922)
- Testing
- Liraglutide 3.0 mg
- Where
- 54 sites in United States, Canada and 5 more
- Volunteers
- 396 people
- Sponsor
- Novo Nordisk A/S
Short Bowel Syndrome
Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)
Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.
- Trial name
- SLIPS (NCT03371862)
- Testing
- Liraglutide Pen Injector [Victoza]
- Where
- United Kingdom
- Sponsor
- Imperial College London
Smoking Cessation, Weight, Body
Daily Liraglutide for Nicotine Dependence
This clinical research trial examines the effects of the GLP-1 receptor agonist liraglutide on smoking behavior, food intake, and weight gain.
- Trial name
- DAL (NCT03712098)
- Testing
- Liraglutide, Smoking Cessation Counseling
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Rebecca Ashare
Metabolism and Nutrition Disorder, Obesity
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America. The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese…
- Trial name
- NCT01272219
- Testing
- liraglutide
- Where
- 226 sites in United States, Argentina and 27 more
- Volunteers
- 3,731 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus
Type 2 diabetes mellitus (T2DM) can impaire cognitive function,the prevalence of Alzheimer's Disease(AD) in T2DM patients is 1.5 to 2.5 times higher than the general population.Cognitive impairment seriously affects the health…
- Trial name
- NCT03707171
- Testing
- Liraglutide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Third Military Medical University
Type 2 Diabetes
The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis
This study aims to evaluate the mechanisms underlying the effect of incretin therapy on lipoprotein metabolism in subjects with type 2 diabetes and to study the effect of liraglutide on hepatic de novo lipogenesis.
- Trial name
- NCT02765399
- Testing
- Liraglutide
- Where
- Finland
- Volunteers
- 23 people
- Sponsor
- Helsinki University Central Hospital
Obesity
Lifestyle Modification and Liraglutide
This is a 52 week, single center, open-labeled, randomized controlled trial. A total of 150 subjects with obesity, who are free of types 1 and 2 diabetes, as well as contraindications to weight loss, will be randomly assigned to…
- Trial name
- MODEL (NCT02911818)
- Testing
- CMS-recommended lifestyle counseling, Liraglutide 3.0mg, Portion-Controlled Diet
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Type 2 Diabetes, Microvascular Dysfunction
Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.
The purpose of the study is to determine if a GLP-1 agonist improves microvascular perfusion in the heart of patients with type 2 diabetes
- Trial name
- EGOFIP (NCT01931982)
- Testing
- Victoza
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Bispebjerg Hospital
Bipolar Disorder, Major Depressive Disorder
Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists
Cognitive deficits are a core feature across disparate brain disorders, being highly prevalent and pervasive. Impairments in executive function are one of the most consistent findings in clinical and meta-analytical studies and…
- Trial name
- COGDYS-GLP1 (NCT02423824)
- Testing
- Liraglutide
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University Health Network, Toronto
Diabetes, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)
This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under…
- Trial name
- NCT02321878
- Testing
- liraglutide
- Where
- 5 sites in Japan
- Volunteers
- 1,092 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes
Insulin therapy is frequently needed to achieve adequate glycaemic control in type 2 diabetes. Although insulin is an effective treatment modality, this is often at the expense of significant weight gain.
- Trial name
- ELEGANT (NCT01392898)
- Testing
- liraglutide, Insulin
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- Radboud University Medical Center
Morbid Obesity
Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.
Our primary objective is to assess the effect of Liraglutide on weight loss in patients who have undergone secondary bariatric surgeries.
- Trial name
- NCT05285397
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
Overweight, Obesity
Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity
This study will look at participants' body weight from the start to the end of the study. The study will last for about 1½ years.
- Trial name
- STEP 8 (NCT04074161)
- Testing
- Semaglutide, Liraglutide
- Where
- 19 sites in United States
- Volunteers
- 338 people
- Sponsor
- Novo Nordisk A/S